Fang C, D’Souza B, Thompson CF, et al. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Med Chem Lett. 2014;5(12):1308–1312.
Pearlstein RA, Hu QY, Zhou J, Yowe D, et al. New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap. Proteins. 2010;78(12):2571–2586.
Virendar Kaushik, Ph.D.
Virendar Kaushik is the director of biochemistry/biophysics within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. His lab uses biochemistry, enzymology, and orthogonal biophysical approaches such as nuclear magnetic resonance, isothermal titration calorimetry, differential scanning calorimetry, surface plasmon resonance, and liquid chromatography/mass spectrometry to identify, validate, and mechanistically characterize potential small molecule therapeutics. The group applies both fragment-based drug discovery and high-throughput screening to support therapeutic areas including cardiovascular, metabolic, inflammatory, and oncologic diseases.
Before coming to the Broad Institute in April 2012, Kaushik was an investigator within the Cardiovascular and Metabolic Disease Area at the Novartis Institutes for Biomedical Research, Inc. (NIBRI). His focus was on developing and executing the biochemistry strategy for therapeutics projects, and leading cross-functional pre-clinical discovery project teams. Prior to NIBRI, Kaushik did research on metabolic diseases and obesity at
Kaushik received his PhD in nutritional biochemistry from Tufts University and his B.A. (biology) and M.A. (physiology) degrees from Boston University. He currently serves as an adjunct assistant professor at Tufts University’s Friedman School of Nutrition Science and Policy.
Contact Virendar Kaushik via email at firstname.lastname@example.org.